Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06003790 · ClinicalTrials.gov registry record · NA

Facilitators and Barriers to the Clinical Implementation of MR-001

A NA study of Chronic Stroke, sponsored by MedRhythms.

Completed
Registry status
NA
Development phase
31
Enrollment target
3
Study locations

NCT06003790: Completed NA study of Chronic Stroke, sponsored by MedRhythms.

NCT06003790 is a NA study of Chronic Stroke that has completed, run by MedRhythms. The registered enrollment target is 31 participants, below the 42-participant average among 20 other Chronic Stroke trials with a reported enrollment target (26% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06003790, a NA study of Chronic Stroke, has completed, sponsored by MedRhythms.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
3
Study locations

Study Summary

This is a single arm, multi-site, prospective hybrid implementation and feasibility trial. The primary purpose of this trial is to gather data on the facilitators and barriers to clinical implementation of MR-001 for patients with chronic stroke who experience walking impairments. Secondarily, the trial will evaluate the feasibility of MR-001 clinically impacting walking capacity, quality of life, mood, and cognition. The goal of this single arm, multi-site, prospective hybrid implementation and feasibility trial is to gather data on the facilitators and barriers to clinical implementation of MR-001 for patient with chronic stroke who experience walking impairments. The main questions it aims to answer are: 1. Enhance understanding of the potential clinical and operational needs and opportunities that may be associated with implementation of MR-001 in various treatment settings. 2. Assess the impact of MR-001 on walking capacity. 3. Assess the impact of MR-001 on quality of life and mood. 4. Assess the impact of MR-001 on cognition. All participants will be prescribed MR-001 and will be asked to walk with it for 30 minutes, 3 times weekly, for 8 weeks.

Primary Outcome

Accomplished by qualitative data collection via prescriber interviews collected up to 3 times during the indicated time frame. These interviews will focus on feedback from prescribers on suitable implementation strategies for deploying MR-001; facilitators and barriers to delivering MR-001 to chronic stroke patients; characterization of the enrolled patient profile, and the enrolled participant experience and satisfaction with MR-001.

Conditions Studied

Interventions

  • DEVICE MR-001

Study Locations (3)

Massachusetts

  • Massachusetts General Hospital - Boston

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Ohio

  • The Cleveland Clinic Foundation - Cleveland

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2023-08-29
Est. Completion 2024-04-30
Phase NA
MedRhythms

4 total trials

What the finished NCT06003790 record still lists

NCT06003790 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 42-participant average among 20 other Chronic Stroke trials with a reported enrollment target (26% lower).

The record links to 1 condition, with Chronic Stroke appearing as the primary indexed condition, and to 1 intervention - of which MR-001 is the first listed.

NCT06003790 reports a single indexed study location in Massachusetts, North Carolina, Ohio.

Frequently Asked Questions

What is clinical trial NCT06003790 about?

NCT06003790 is a clinical study titled "Facilitators and Barriers to the Clinical Implementation of MR-001". This is a single arm, multi-site, prospective hybrid implementation and feasibility trial. The primary purpose of this trial is to gather data on the facilitators and barriers to clinical implementation of MR-001 for patients with chronic stroke who experience walking impairments. Secondarily, the t...

What is the current status of trial NCT06003790?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2023-08-29. Estimated completion is 2024-04-30.

What conditions does trial NCT06003790 study?

This clinical trial studies the following conditions: Chronic Stroke.

What interventions are being tested in trial NCT06003790?

The interventions under investigation include: MR-001 (DEVICE).

Who is sponsoring clinical trial NCT06003790?

This trial is sponsored by MedRhythms, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06003790 being conducted?

This trial has 3 study locations across Massachusetts, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06003790's enrollment target sits among peer trials

31 10th of 20 higher than 11 of 20 other Chronic Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06003790, the US trial registry maintained by the National Library of Medicine. NCT06003790 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.